Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Apr. 13];4(5):s37. Available from: https://skin.dermsquared.com/skin/article/view/986